Policy Developments - The National Medical Products Administration (NMPA) is seeking public opinions on the revised procedures for conditional approval of drug listings to improve the review and approval system [2] Drug and Device Approvals - Xuno Pharmaceutical's oral cancer drug, Abexinostat, is proposed for priority review by the NMPA, aimed at adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies [5] - LuKang Pharmaceutical has received the drug registration certificate for Gefitinib tablets, a first-generation targeted drug for non-small cell lung cancer with EGFR gene mutations [6] Capital Market Activities - Shenzhen Keximingde Medical Technology Co., Ltd. completed a multi-hundred million RMB A+ round financing, with funds allocated for brand building and R&D of soft endoscope products [8] - Buchang Pharmaceutical announced the abandonment of the preferential right to acquire shares in its subsidiary, Shaanxi Modern Innovation, resulting in an 86.50% ownership stake post-transfer [9] - Taiji Group plans to optimize its equity structure by acquiring stakes in its subsidiaries for a nominal price [10] Industry Developments - Chugai Pharmaceutical and Gero PTE have signed a $220 million collaboration agreement to integrate Gero's AI-driven platform into Chugai's R&D strategy for developing therapies for age-related diseases [12] - Kanghua Biotech has terminated its collaboration with Xiran Bochuang on the development of mRNA vaccines for tuberculosis, indicating a strategic shift towards in-house R&D capabilities [13] Shareholder Activities - Guizhou Jin Domain Medical Testing Group announced that major shareholder Guochuang Kaiyuan intends to reduce its stake by up to 1% through market transactions [16] - Haichuang Pharmaceutical reported that shareholder Yingchuang Power has cumulatively reduced its stake by 0.28% [17] - Tongrentang announced the resignation of its executive vice president, Zhang Chunyou, who will continue to serve in a managerial role at a subsidiary [18]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-025 基蛋生物科技股份有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生影响：本案件二审已立案审查，尚未开庭， 也未产生有效判决，暂时无法判断对公司本期利润和期后利润的影响。公司将根 据诉讼进展情况及时履行信息披露义务，敬请广大投资者理性投资，注意投资风 险。 议、会计凭证、会计账簿、财务报表、审计报告及财务会计报告（包括资产负债 表、利润表、现金流量表、资产减值准备明细表、利润分配表、股东权益增减变 动表、其他有关附表）等材料交由基蛋生物查阅和复制； 2、判令基蛋生物有权委托会计师、律师等中介机构执业人员辅助进行上述 查阅和复制事宜； 3、判令本案全部诉讼费由景川诊断承担。 具体内容详见公司于 2024 年 12 月 25 日披露的《基蛋生物：关于公司涉及 诉讼的公告》（公告编号：2024-049）。 一、本次诉讼的基本情况 基蛋生物科技股份有限公司（以下简称"公司"或"基蛋生物"）作 ...

Key Points - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets on July 4, providing insights for investors [2] Group 1: Major Corporate Actions - China Shipbuilding Industry Corporation's absorption and merger with China Shipbuilding Industry Group has been approved by the Shanghai Stock Exchange, pending further regulatory approvals [3] - Aerospace Hongtu's controlling shareholder's action party plans to transfer 5.1% of the company's shares to a private equity fund at a price of 19 yuan per share, totaling 253 million yuan [4] - Guotou Zhonglu plans to acquire 100% of China Electronic Engineering Design Institute through a share issuance, with the transaction price yet to be determined [5] - Haitai Development intends to transfer 100% of its subsidiary's equity for 90.6595 million yuan, aiming to optimize its asset structure [6] - Gensun Bio plans to invest approximately 150 million yuan to build an intelligent production and R&D base, expected to be completed by 2028 [7] - Xinhua Insurance intends to invest 11.25 billion yuan to subscribe to a private equity fund, which has a total size of 22.5 billion yuan [8] - Huaming Equipment has raised its share repurchase fund limit from 200 million yuan to 250 million yuan [9] - Aotewei's controlling shareholders plan to transfer 4.99% of the company's shares through a pricing inquiry [10] - Jianke Institute plans to publicly transfer 40% of its stake in Hubei Jiansheng Engineering Technology Consulting Co., Ltd. [11] - Aerospace Electronics plans to increase capital in its subsidiary to enhance its capabilities in unmanned systems [12] Group 2: Financial Performance - Jin Xin Nong reported a 1.23% year-on-year decline in pig sales revenue for the first half of 2025, totaling 763 million yuan [14] - Tianbang Food's June pig sales revenue decreased by 4.01% month-on-month, with a total of 4.143 billion yuan for the first half of 2025 [15] - GAC Group's June automobile sales fell by 8.22% year-on-year, with a total of 755,300 vehicles sold in the first half of 2025, down 12.48% [16] - Pulite expects a net profit increase of 38.88% to 66.65% for the first half of 2025, driven by growth in modified materials and new energy businesses [18] - Zhuye Group anticipates a net profit increase of 50.97% to 75.23% for the first half of 2025, benefiting from rising precious metal prices [19] - Xindong Lian Ke expects a net profit increase of 144.46% to 199.37% for the first half of 2025, supported by sufficient orders and revenue growth [20] - Zhongce Rubber forecasts a net profit decrease of 6.3% to 11.81% for the first half of 2025, due to a one-time gain in the previous year [21] - *ST Sihua expects a net loss of 11 million to 17 million yuan for the first half of 2025, despite significant sales order growth [22] - Sankeshu anticipates a net profit increase of 80.94% to 119.04% for the first half of 2025, driven by growth in retail business and improved gross margins [23] Group 3: Major Contracts and Shareholding Changes - Hongsheng Huayuan's subsidiary is expected to win a bid for a project worth approximately 1.127 billion yuan from the Southern Power Grid [25] - Times New Materials signed contracts worth approximately 2.711 billion yuan for wind turbine blade sales in the second quarter of 2025 [26] - Guojian Group's controlling shareholder reduced its holdings of convertible bonds by 900,000 units, accounting for 11.25% of the total issuance [27] - Yue Wanniang's controlling shareholder plans to reduce its stake by up to 6% through various trading methods [28] - Maipu Medical's shareholder plans to reduce its stake by up to 665,100 shares, representing 0.9999% of the total shares [29] - Jiulian Technology's directors and senior management plan to reduce their holdings by up to 2.61% of the total shares [30] - *ST Huawang's shareholder plans to reduce its stake by up to 1.76% through trading methods [32]

Financial Performance - Whirlpool expects a net profit of approximately 205 million yuan for the first half of 2025, an increase of about 174 million yuan or approximately 559% year-on-year [2] - Chipmotion Technology anticipates a net profit between 138 million to 169 million yuan for the first half of 2025, representing a year-on-year growth of approximately 144.46% to 199.37% [2] Mergers and Acquisitions - China Shipbuilding's absorption merger with China Shipbuilding Industry Corporation has been approved by the Shanghai Stock Exchange, pending further regulatory approvals [3] - Guotou Zhonglu plans to acquire 100% of China Electronic Engineering Design Institute through a share issuance, which constitutes a major asset restructuring [4] Shareholder Actions - Aotewei's actual controllers plan to transfer 4.99% of the company's shares, totaling 15.75 million shares, due to personal funding needs [5] - Yaguang Technology's chairman has been placed under detention, but the company's operations remain normal [5] Industry Developments - Ningbo Port expects a 9.8% year-on-year increase in container throughput for the first half of 2025 [8] - Three Trees anticipates a net profit growth of 80.94% to 119.04% for the first half of 2025 [8] - Zhuhai Group expects a net profit increase of 50.97% to 75.23% for the first half of 2025 [8] Project Wins - Sanxing Medical's subsidiary has pre-qualified for a 306 million yuan project with Southern Power Grid [8] - Hopu Co., Ltd. has jointly won a 449 million yuan shared energy storage demonstration project [8] - Hongsheng Huayuan's subsidiary has pre-qualified for an 1.127 billion yuan project with Southern Power Grid [8]

Corporate Announcements - Aerospace Hongtu's controlling shareholder plans to transfer 5.1% of the company's shares, totaling 13.33 million shares at a price of 19 yuan per share, amounting to 253 million yuan [3] - Haitai Development intends to transfer 100% equity of its subsidiary for 90.66 million yuan, which is part of its strategic transformation to optimize asset structure [4] - G-Biosciences plans to invest approximately 150 million yuan to build an intelligent production and R&D base, expected to be completed by 2028 [5] - New China Life Insurance intends to invest 11.25 billion yuan to subscribe to a private fund, which has a total scale of 22.5 billion yuan [6] - Huaming Equipment has increased its share repurchase fund limit from 200 million yuan to 250 million yuan [7] Performance Updates - Jinxinnong reported a 1.23% year-on-year decline in pig sales revenue for the first half of 2025, totaling 763 million yuan [9] - Tianbang Foods reported a 4.01% month-on-month decline in June sales revenue for commodity pigs, totaling 675 million yuan [10] - GAC Group's June automobile sales were 150,100 units, a year-on-year decrease of 8.22% [11] - Pulit expects a net profit of 200 million to 240 million yuan for the first half of 2025, a year-on-year increase of 38.88% to 66.65% [12] - Zhuyue Group anticipates a net profit of 560 million to 650 million yuan for the first half of 2025, a year-on-year increase of 50.97% to 75.23% [14] - Xindong Lianke expects a net profit of 138 million to 169 million yuan for the first half of 2025, a year-on-year increase of 144.46% to 199.37% [15] - Zhongce Rubber expects a net profit of 2.24 billion to 2.38 billion yuan for the first half of 2025, a year-on-year decrease of 6.3% to 11.81% [16] - ST Sitong anticipates a net loss of 11 million to 17 million yuan for the first half of 2025, compared to a loss of 9.08 million yuan in the same period last year [17] Major Contracts - Hongsheng Huayuan's subsidiary is expected to win a bid for a Southern Power Grid project worth approximately 1.127 billion yuan, accounting for 11.12% of the company's 2024 revenue [19] - Times New Materials signed contracts worth approximately 2.711 billion yuan for wind turbine blade sales in the second quarter of 2025 [20] Shareholding Changes - Guojian Group's controlling shareholder reduced its holdings of convertible bonds by 900,000 units, accounting for 11.25% of the total issuance [22]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-024 基蛋生物科技股份有限公司 本次投资不构成关联交易，也不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。 二、审议情况 2025 年 7 月 4 日，公司召开第四届董事会第六次会议及第四届监事会第六 次会议，审议通过了《关于投资建设智能化生产研发基地的议案》，同意公司使 用自有资金投资建设智能化生产研发基地。上述议案无需经公司股东大会审议。 三、投资项目的基本情况 关于投资建设智能化生产研发基地的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资项目名称：智能化生产研发基地 投资金额：预计总投资约 1.5 亿元人民币，包含土地价款、建筑主体工 程及配套设施工程费用。项目最终投资总额以实际投资金额为准。 相关风险提示：在项目建设过程中，可能存在相关政策、宏观经济等方 面的不确定性风险，有可能会影响项目的正常实施。公司将根据实际情况，依法 合规推行项目进展，规避项目风险。公司将根据项目进展情况及时履行信息披露 义务，敬请广大投资 ...

Group 1 - The company plans to invest 150 million yuan to build an intelligent production and R&D base, which includes land costs, main construction, and supporting facility expenses [1] - The project will cover an area of approximately 40,010.27 square meters, with a total construction area of about 65,538.81 square meters, featuring a four-story comprehensive factory, high-standard storage center, and supporting R&D office facilities [1] - Upon completion, the project will enhance the production capacity for instruments and reagents in product lines such as chemiluminescence, biochemistry, and hematology [1] Group 2 - The company has obtained the necessary land for construction and relevant permits, with an expected completion date in 2028 [1]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-023 基蛋生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 3. 分配方案： A 股每股现金红利0.09元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 | | --- | --- | --- | --- | --- | | | | | | 日 | | Ａ股 | 2025/6/16 | － | 2025/6/17 | 2025/6/17 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 22 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本5 ...

Core Points - The company announced a cash dividend of 0.09 yuan per share (before tax) for its A shares, totaling approximately 45.64 million yuan to be distributed to shareholders [1][2] - The dividend distribution plan was approved at the annual general meeting held on May 22, 2025 [1] - The record date for the dividend is June 16, 2025, with the last trading day and ex-dividend date also set for June 17, 2025 [1][2] Dividend Distribution Details - The total number of shares before the dividend distribution is 507,153,517 [2] - The cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch [2] - Shareholders who have not completed designated trading will have their dividends held by the China Securities Depository and Clearing Corporation until they complete the necessary trading [2] Taxation Information - Individual shareholders holding shares for more than one year are exempt from personal income tax on dividend income, while those holding for one year or less will not have tax withheld at the time of distribution [3][4] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.081 yuan per share [5][6] - Other institutional investors and corporate shareholders will not have tax withheld by the company, and they are responsible for determining their own tax obligations [6]

基蛋生物科技股份有限公司 2024年年度权益分派实施公告 证券代码：603387 证券简称：基蛋生物 公告编号：2025-023 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 | | --- | --- | --- | --- | --- | | | | | | 日 | | Ａ股 | 2025/6/16 | － | 2025/6/17 | 2025/6/17 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 22 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.09元（含税） 相关日期 1. 实施办法 无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股 权登记日上海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定 交易的股东派发。已办理指定交易的投资者可于红 ...